Pfizer goes to Court to allow competition for biologics and expand options for patients
- Details
- Category: Pfizer
To ensure patients and providers have access to important, lower cost biosimilar medicines, Pfizer (NYSE:PFE) has filed suit in the U.S. District Court for the Eastern District of Pennsylvania against Johnson & Johnson (J&J). The suit alleges that J&J's exclusionary contracts and other anticompetitive practices have denied U.S. patients access to therapeutic options and undermined the benefits of robust price competition in the innovative and growing biologics marketplace for patients.
IPF World Week 2017: Boehringer Ingelheim helps healthcare professionals to 'listen for the sounds of IPF'
- Details
- Category: Boehringer Ingelheim
IPF is a progressive and debilitating disease which causes continual and irreversible damage to the lungs.(1) Early diagnosis is vital because without appropriate medical intervention, the opportunity to slow disease progression is lost. However, diagnosis can be challenging.(1,2) This year for IPF World Week (16 - 24 September), Boehringer Ingelheim is raising awareness of
Johnson & Johnson announces collaboration with U.S. Department of Health and Human Services to fight influenza
- Details
- Category: Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) announced that Janssen Research & Development LLC (Janssen) are collaborating with the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to develop a comprehensive portfolio of therapeutics and vaccines to protect communities in the event of an influenza pandemic and other infectious disease threats.
Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data
- Details
- Category: Novartis
Novartis has announced, first of its kind Phase III data showing Cosentyx® (secukinumab) delivered high and long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis at 5 years[1]. These data were presented for the first time at the 26th European Academy of Dermatology and Venereology (EADV) Congress in Geneva, Switzerland.
Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for ENHANZE technology
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced a global collaboration and license agreement to develop subcutaneously administered Bristol-Myers Squibb immuno-oncology medicines using Halozyme’s ENHANZE® drug-delivery technology.
More people treated with once-weekly semaglutide achieved reductions in both glucose and weight vs. comparator treatments
- Details
- Category: Novo Nordisk
A post-hoc analysis of the SUSTAIN 1-5 trials demonstrated that a greater proportion of adults with type 2 diabetes achieved a clinically meaningful reduction in both HbA1c and body weight with once-weekly semaglutide vs. comparator treatments. Comparators included placebo, sitagliptin, insulin glargine U100 or exenatide extended release (ER).
AstraZeneca presents new results identifying severe asthma patients who would benefit most from benralizumab
- Details
- Category: AstraZeneca
AstraZeneca has announced results from a subgroup analysis of the SIROCCO and CALIMA Phase III trials. The results confirm benralizumab's compelling efficacy and identify key factors that predict which patients with severe, uncontrolled asthma would respond best to treatment with this potential new medicine.
More Pharma News ...
- Merck set to join forces with Project Data Sphere to pioneer Global Oncology Big Data Alliance
- Sanofi and Regeneron announce that cemiplimab (REGN2810) has received FDA Breakthrough Therapy designation for advanced cutaneous squamous cell carcinoma
- Merck to acquire Rigontec, RIG-I therapeutics pioneer, advancing leadership in immuno-oncology
- Bristol-Myers Squibb completes previously announced acquisition of IFM Therapeutics
- Tezepelumab significantly reduced asthma exacerbations for a broad population of patients with severe uncontrolled asthma
- Bristol-Myers Squibb employees ride across the U.S. to raise money to support cancer research by Stand Up To Cancer
- Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm), a biosimilar to Humira®